Novo Nordisk's sales increased by 31% to DKK 232.26 billion, and Net profit increased by 51% to DKK 83.68 billion in 2023. Analysts polled by Visible Alpha were expecting 82.55 billion kroner in net profit, while sales were estimated at 229.36 billion kroner.
諾和諾德的銷售額增長了31％，達到2322.6億丹麥克朗，2023年淨利潤增長了51％，達到836.8億丹麥克朗。Visible Alpha調查的分析師預計淨利潤爲825.5億克朗，而銷售額估計爲2293.6億克朗。
Sales within Diabetes and Obesity care increased by 38% in Danish kroner to DKK 215.1 billion (42% at constant exchange rates), mainly driven by GLP-1 diabetes sales growth of 48% in Danish kroner (52% at CER) and Obesity care growing by 147% in Danish Kroner to DKK 41.6 billion (154% at CER). Rare disease sales decreased by 16% measured in Danish kroner (15% at CER) reflecting a reduction in manufacturing output.
糖尿病和肥胖症護理領域的銷售額以丹麥克朗計算增長了38％，達到2151億丹麥克朗（按固定匯率計算爲42％），這主要是由以丹麥克朗計算的 GLP-1 糖尿病銷售額增長48％（按恒定匯率計算爲52％），以及肥胖護理以丹麥克朗計算增長147％，達到416億丹麥克朗（按恒定匯率計算爲154％）。以丹麥克朗計算，罕見病銷售額下降了16％（按CER計算爲15％），這反映了製造業產出的下降。
For 2024, the company expects 18% to 26% sales growth and 21% to 29% operating profit growth at constant exchange rates. The increase in sales and operating profit in Danish kroner is expected to be 1 percentage point and 2 percentage points lower than at constant exchange rates, respectively.
該公司預計，按固定匯率計算，2024年的銷售額將增長18％至26％，營業利潤增長21％至29％。以丹麥克朗計算，銷售額和營業利潤的增長預計將分別比固定匯率低1個百分點和2個百分點。